• TG Therapeutics, Inc. reported past second-quarter 2026 results with revenue of US$240.34 million versus US$141.15 million a year earlier, while net income declined to US$7.78 million from US$28.19 million and diluted EPS from continuing operations was US$0.05 compared with US$0.17.
• Despite weaker profitability, management raised full-year 2026 global revenue guidance to approximately US$950 million, underscoring confidence in the commercial trajectory of its B-cell disease franchise.
• We’ll now examine how this strong revenue growth alongside higher full-year guidance may influence TG Therapeutics’ existing investment narrative.

Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

TG Therapeutics Investment Narrative Recap

To own TG Therapeutics, you have to believe BRIUMVI can sustain meaningful share in B‑cell–mediated diseases while the company broadens its autoimmune footprint. The latest quarter delivered strong top line growth but softer profitability, and the higher 2026 revenue guidance reinforces the near term catalyst around continued BRIUMVI uptake. However, reliance on a single IV franchise and mounting payer pressure for lower cost, self administered options remain the key risks that could quickly reframe this story.

The most relevant recent announcement is management’s decision on 3 August 2026 to lift full year 2026 global revenue guidance to about US$950 million. That move ties directly to the same commercial engine behind the anticipated launch of subcutaneous BRIUMVI, which consensus views as a major upcoming catalyst. If subcutaneous adoption or pricing comes in below expectations, the combination of higher revenue targets and concentrated exposure to B‑cell therapies could cut both ways for shareholders.

Yet beneath the strong guidance, investors should still be alert to how payer pressure on high cost MS drugs could affect BRIUMVI’s pricing and long term margin profile…

TG Therapeutics' narrative projects $1.7 billion revenue and $616.2 million earnings by 2029. This requires 33.2% yearly revenue growth and about a $154.3 million earnings increase from $461.9 million today.

Uncover how TG Therapeutics' forecasts yield a $51.71 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Before this earnings beat, the most optimistic analysts already modeled revenue climbing about 42 percent per year to roughly US$2.0 billion, assuming rapid subcutaneous BRIUMVI uptake. This quarter’s raised US$950 million guidance might either support that faster growth story or prompt a rethink of how much risk you are taking on concentrated pricing and regulatory assumptions.

Explore 6 other fair value estimates on TG Therapeutics - why the stock might be worth over 3x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your TG Therapeutics research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free TG Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate TG Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.